ES2656614T3 - Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos - Google Patents

Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos Download PDF

Info

Publication number
ES2656614T3
ES2656614T3 ES12862921.9T ES12862921T ES2656614T3 ES 2656614 T3 ES2656614 T3 ES 2656614T3 ES 12862921 T ES12862921 T ES 12862921T ES 2656614 T3 ES2656614 T3 ES 2656614T3
Authority
ES
Spain
Prior art keywords
cells
cell
culture
isolated cell
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12862921.9T
Other languages
English (en)
Spanish (es)
Inventor
Amit Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48698707&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2656614(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2656614T3 publication Critical patent/ES2656614T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0665—Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0654—Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
ES12862921.9T 2011-12-30 2012-12-31 Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos Active ES2656614T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161582070P 2011-12-30 2011-12-30
US201161582070P 2011-12-30
US201261591211P 2012-01-26 2012-01-26
US201261591211P 2012-01-26
PCT/US2012/072331 WO2013102219A1 (en) 2011-12-30 2012-12-31 Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses

Publications (1)

Publication Number Publication Date
ES2656614T3 true ES2656614T3 (es) 2018-02-27

Family

ID=48698707

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12862921.9T Active ES2656614T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos
ES17191442T Active ES2890126T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17191442T Active ES2890126T3 (es) 2011-12-30 2012-12-31 Métodos y composiciones para la obtención clínica de una célula alogénica y usos terapéuticos

Country Status (12)

Country Link
US (8) US9803176B2 (https=)
EP (2) EP3321355B1 (https=)
JP (1) JP6548897B2 (https=)
CA (2) CA2862661C (https=)
DK (1) DK3321355T3 (https=)
ES (2) ES2656614T3 (https=)
HR (1) HRP20211373T1 (https=)
HU (1) HUE056817T2 (https=)
PL (1) PL3321355T3 (https=)
PT (1) PT3321355T (https=)
SI (1) SI3321355T1 (https=)
WO (1) WO2013102219A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8182840B2 (en) 2005-09-27 2012-05-22 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and therapy for scar reversal and inhibition
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
ES2822301T3 (es) 2011-06-10 2021-04-30 Tissuetech Inc Métodos de procesamiento de tejidos de soporte fetal
KR101662405B1 (ko) * 2013-12-12 2016-10-05 사회복지법인 삼성생명공익재단 줄기세포 유래 엑소좀을 유효성분으로 포함하는 뇌혈관 질환 치료용 약학적 조성물
US9919011B2 (en) 2014-03-18 2018-03-20 Samsung Life Public Welfare Foundation Method for treating an inflammatory brain disease comprising administering a stem cell-derived exosome
EP3146039A4 (en) * 2014-05-21 2017-11-29 MiMedx Group, Inc. Micronized wharton's jelly
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
WO2016007554A1 (en) 2014-07-08 2016-01-14 Mimedx Group, Inc. Micronized wharton's jelly
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
JP2018516869A (ja) 2015-05-20 2018-06-28 ティッシュテック，インク． 上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
EP3336176B1 (en) * 2015-08-12 2022-04-20 Cha Biotech Co., Ltd. Improved umbilical cord-derived adhesive stem cells, preparation method therefor, and use thereof
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
CA3029233A1 (en) * 2016-06-24 2017-12-28 Osiris Therapeutics, Inc. Human tissue derived compositions and uses thereof
US11649436B2 (en) 2016-12-02 2023-05-16 The Catholic University Of Korea Industry-Academic Cooperation Foundation Exosome for stimulating T cell and pharmaceutical use thereof
KR101864234B1 (ko) * 2017-07-04 2018-06-04 인하대학교 산학협력단 음경해면체 유래 엑소좀을 유효성분으로 포함하는, 발기부전 예방, 개선 또는 치료용 조성물
US11285177B2 (en) 2018-01-03 2022-03-29 Globus Medical, Inc. Allografts containing viable cells and methods thereof
CN108239621B (zh) * 2018-01-24 2020-08-18 北京臻溪谷医学研究中心（有限合伙） 一种胎盘亚全能干细胞分离、扩增、冻存、复苏干细胞的方法
JP7565927B2 (ja) 2019-01-16 2024-10-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション ヒト臍帯間葉系幹細胞シート及びその製造方法
US20210386790A1 (en) * 2019-01-16 2021-12-16 University Of Utah Research Foundation Use of mesenchymal stem cell sheets for preventing uterine scar formation
US20230338428A1 (en) * 2020-09-08 2023-10-26 Amit Patel Allogenic umbilical cord stem cells for treating severe respiratory conditions
US20230057957A1 (en) * 2021-08-23 2023-02-23 Therapeutic Solutions International, Inc. Umbilical cord mesenchymal stem cells for treatment of chronic obstructive pulmonary disease and lung degeneration
US20230295569A1 (en) * 2022-03-15 2023-09-21 Creative Medical Technologies, Inc. Therapeutic regenerative cells
US20230293598A1 (en) * 2022-03-15 2023-09-21 Narkeshyo LLC Prevention of radiation exposure associated pathology by treatment with umbilical cord derived regenerative cells
US20230364148A1 (en) * 2022-05-12 2023-11-16 Therapeutic Solutions International, Inc. Inhibition and reversion of chronic obstructive pulmonary disease (copd) by endothelial cell regeneration
CN119452078A (zh) * 2022-06-29 2025-02-14 富士胶片控股美国公司 Ipsc来源的星形胶质细胞及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
US20030161818A1 (en) 2002-02-25 2003-08-28 Kansas State University Research Foundation Cultures, products and methods using stem cells
EP2277992A3 (en) 2003-02-11 2011-03-02 John E. Davies Progenitor cells from Wharton's jelly of human umbilical cord
EP2399990B1 (en) 2003-06-27 2015-07-22 DePuy Synthes Products, Inc. Cells derived from post-partum umbilical cord for use in treatment of disease of the heart and circulatory system
KR101322889B1 (ko) * 2004-08-16 2013-10-30 셀리서치 코포레이션 피티이 리미티드 제대의 양막으로부터 줄기/전구세포의 추출
WO2007106089A1 (en) 2006-03-14 2007-09-20 Spherical Dynamics, Inc. System for and method for psychological assessment
NZ612888A (en) * 2007-02-12 2015-02-27 Anthrogenesis Corp Treatment of inflammatory diseases using placental stem cells
PT103843B (pt) * 2007-10-04 2008-08-12 Medinfar Produtos Farmaceutico Método de isolamento de células precursoras a partir do cordão umbilical humano
DK2375907T3 (da) * 2008-11-21 2019-06-11 Celularity Inc Behandling af sygdomme, lidelser eller tilstande i lungerne under anvendelse af placentaceller
CN101748096B (zh) 2008-12-17 2013-03-13 北京汉氏联合生物技术有限公司 亚全能干细胞、其制备方法及其用途
CN102439136A (zh) 2009-03-26 2012-05-02 加州大学校董 产生用于疾病修饰的抑制性rna的间充质干细胞
CN102686722B (zh) * 2009-09-23 2014-11-05 达芬奇生物科技有限责任公司 脐带衬干细胞及其分离和培养方法和材料
CN101890050B (zh) * 2010-07-14 2012-07-04 江苏大学 脐带间质干细胞来源膜性囊泡及其应用
EP2540819A1 (en) 2011-06-27 2013-01-02 Rheinisch-Westfälische Technische Hochschule Aachen (RWTH) Method for cultivating cells in platelet-lysate-containing medium
US20210355437A1 (en) 2015-09-02 2021-11-18 Restem Llc Factor rich product from umbilical cord mesenchymal stem cells

Also Published As

Publication number Publication date
EP2798058A4 (en) 2015-05-20
PL3321355T3 (pl) 2021-12-27
HRP20211373T1 (hr) 2021-11-26
US20220251513A1 (en) 2022-08-11
ES2890126T3 (es) 2022-01-17
DK3321355T3 (da) 2021-11-08
CA2862661A1 (en) 2013-07-04
WO2013102219A1 (en) 2013-07-04
JP6548897B2 (ja) 2019-07-24
US20130216505A1 (en) 2013-08-22
US20220251514A1 (en) 2022-08-11
US20260078347A1 (en) 2026-03-19
EP3321355B1 (en) 2021-08-25
EP2798058B1 (en) 2017-10-18
US20250346865A1 (en) 2025-11-13
US20220041992A1 (en) 2022-02-10
CA2862661C (en) 2021-05-25
EP3321355A1 (en) 2018-05-16
EP2798058A1 (en) 2014-11-05
PT3321355T (pt) 2021-09-28
SI3321355T1 (sl) 2021-11-30
US20220251515A1 (en) 2022-08-11
CA3113484A1 (en) 2013-07-04
JP2015503918A (ja) 2015-02-05
HUE056817T2 (hu) 2022-03-28
US12441986B2 (en) 2025-10-14
US9803176B2 (en) 2017-10-31
US20190218519A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
ES2656614T3 (es) Métodos y composiciones para la derivación clínica de células alogénicas y sus usos terapéuticos
ES2776408T3 (es) Método de proliferación celular y agente farmacéutico para reparación y regeneración de tejido
ES2613930T3 (es) Procedimiento de cultivo de células procedentes de tejido adiposo y sus aplicaciones
ES2880349T3 (es) Uso de células madre estromales derivadas del tejido adiposo en el tratamiento de la fístula
US20150139952A1 (en) Methods, compositions, cells, and kits for treating ischemic injury
TW201138791A (en) Angiogenesis using placental stem cells
CN107028980A (zh) 用于治疗心脏疾病的药物组合物
Cheng et al. Influence of human platelet lysate on extracellular matrix deposition and cellular characteristics in adipose-derived stem cell sheets
WO2010056341A2 (en) Compositions and methods for tissue repair
Mayfield et al. Resident cardiac stem cells and their role in stem cell therapies for myocardial repair
US20170296591A1 (en) Cardiosphere-derived cells (cdcs) as therapeutic agents for pulmonary hypertension
Cruz et al. Regenerative potential of the cartilaginous tissue in mesenchymal stem cells: update, limitations, and challenges☆
BR112021013158A2 (pt) Método para tratar a dor lombar
Oh et al. Lung regeneration therapy for chronic obstructive pulmonary disease
WO2012065024A1 (en) Compositions, cells, kits and methods for autologous stem cell therapy
ES2623142T3 (es) Un método para amplificar las células madre cardíacas in vitro e in vivo
ES2366701T3 (es) Técnicas in vitro para su uso con células madre.
KR20160144780A (ko) 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법
US20190255117A1 (en) Synoviolin expression inhibitor containing mesenchymal stem cell or culture supernatant thereof
Gao Stem Cell and Drug Delivery Systems for Promoting Angiogenesis and Myogenesis in Ischemic Limbs
Kjems et al. Extracellular vesicular miRNAs in osteoblastogenesis
HL 3rd EACTS Meeting on Cardiac and Pulmonary Regeneration Berlin-Brandenburgische Akademie, Berlin, Germany, 14–15 December 2012
Gojo et al. Cardiac Regenerative Medicine Cellular Therapy and Tissue Engineering